The provider administers chimeric antigen receptor T–cell (CAR–T) therapy, genetically modified T cells extracted from a patient’s own blood, by intravenous infusion to a patient to treat leukemia and other types of blood cancer.
For clinical responsibility, terminology, tips and additional info
start codify free trial.